VJOncology is committed to improving our service to you

ESMO 2019 | PATRIOT: ATR inhibitor monotherapy in advanced solid tumors

VJOncology is committed to improving our service to you

Kevin Harrington

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, discusses the PATRIOT trial (NCT02223923), a Phase I study to assess the tolerability, safety and biological effects of the ATR inhibitor AZD6738 as a monotherapy and in combination with palliative radiation therapy in patients with advanced solid tumors. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter